{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:30:00Z","timestamp":1760239800972,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.hoc.2023.04.002","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T15:45:03Z","timestamp":1684511103000},"page":"659-670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Implications of Genomic Profile in Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.1016","volume":"37","author":[{"given":"David F.","family":"Moreno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.hoc.2023.04.002_bib1","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.002_bib2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2023.04.002_bib3","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.002_bib4","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.002_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr\u00f6m Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2023.04.002_bib6","first-page":"1198","article-title":"Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia and Its Impact on Treatment Strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J\u00a0Clin Orthod"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.002_bib7","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/2643-3230.BCD-21-0043","article-title":"Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia","volume":"2","author":"Kaushal","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.002_bib8","doi-asserted-by":"crossref","first-page":"eabl4644","DOI":"10.1126\/sciadv.abl4644","article-title":"Preneoplastic somatic mutations including MYD88 L265P in lymphoplasmacytic lymphoma","volume":"8","author":"Rodriguez","year":"2022","journal-title":"Sci Adv"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.002_bib9","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/bloodadvances.2022008876","article-title":"Waldenstr\u00f6m Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late Copy Number Aberrations","volume":"7","author":"Maclachlan","year":"2022","journal-title":"Blood Advances"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.002_bib10","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/2159-8290.CD-18-0873","article-title":"A\u00a0Recurrent Activating Missense Mutation in Waldenstr\u00f6m Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation","volume":"9","author":"Roos-Weil","year":"2019","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.002_bib11","first-page":"585","article-title":"Identification of two DNA methylation subtypes of Waldenstr\u00f6m\u2019s macroglobulinemia with plasma and memory B cell features","volume":"136","author":"Roos-Weil","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.002_bib12","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1038\/s41467-018-06541-2","article-title":"Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenstr\u00f6m macroglobulinemia","volume":"9","author":"McMaster","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.002_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2016-03-708263","article-title":"Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenstr\u00f6m macroglobulinemia","volume":"128","author":"Hunter","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.002_bib14","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic Landscape of CXCR4 Mutations in Waldenstr\u00f6m Macroglobulinemia","volume":"22","author":"Poulain","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.hoc.2023.04.002_bib15","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1182\/blood-2014-03-564583","article-title":"C1013G\/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma","volume":"123","author":"Roccaro","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.002_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.hoc.2023.04.002_bib17","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the genomic landscape of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Advances"},{"issue":"15","key":"10.1016\/j.hoc.2023.04.002_bib18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.002_bib19","first-page":"52","article-title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstr\u00f6m\u2019s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J\u00a0Clin Orthod"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.002_bib20","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematology"},{"issue":"3","key":"10.1016\/j.hoc.2023.04.002_bib21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","article-title":"CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib","volume":"187","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.hoc.2023.04.002_bib22","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A\u00a0randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.002_bib23","first-page":"63","article-title":"Venetoclax in Previously Treated Waldenstr\u00f6m Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J\u00a0Clin Orthod"},{"issue":"16","key":"10.1016\/j.hoc.2023.04.002_bib24","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia: long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Advances"},{"issue":"17","key":"10.1016\/j.hoc.2023.04.002_bib25","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.2021012953","article-title":"Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenstr\u00f6m macroglobulinemia","volume":"138","author":"Treon","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.04.002_bib26","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2021-144706","article-title":"Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia with MYD88 and CXCR4 Mutations","volume":"138","author":"Treon","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.002_bib27","first-page":"565","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr\u00f6m Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J\u00a0Clin Orthod"},{"issue":"9","key":"10.1016\/j.hoc.2023.04.002_bib28","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","article-title":"Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia","volume":"5","author":"Tomowiak","year":"2021","journal-title":"Blood Advances"},{"issue":"4","key":"10.1016\/j.hoc.2023.04.002_bib29","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.16086","volume":"187","author":"Varettoni","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2023.04.002_bib30","first-page":"18502","article-title":"Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstr\u00f6m macroglobulinaemia","volume":"bjh","author":"Moreno","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2023.04.002_bib31","first-page":"00394","article-title":"Progression Risk Stratification of Asymptomatic Waldenstr\u00f6m Macroglobulinemia","volume":"19","author":"Bustoros","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.04.002_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bjh.17691","article-title":"Disease outcomes and biomarkers of progression in smouldering Waldenstr\u00f6m macroglobulinaemia","volume":"195","author":"Zanwar","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.002_bib33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bjh.17028","article-title":"6q deletion in Waldenstr\u00f6m macroglobulinaemia negatively affects time to transformation and survival","volume":"192","author":"Garc\u00eda-Sanz","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.002_bib34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.002_bib35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/diagnostics11050779","article-title":"MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation","volume":"11","author":"Ferrante","year":"2021","journal-title":"Diagnostics"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.002_bib36","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/s41375-018-0197-7","article-title":"Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies","volume":"32","author":"Bagratuni","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2023.04.002_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/bloodadvances.2021005354","article-title":"Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies","volume":"6","author":"Bagratuni","year":"2022","journal-title":"Blood Advances"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.002_bib38","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"27","author":"Jim\u00e9nez","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2023.04.002_bib39","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom\u2019s macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.04.002_bib40","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr\u00f6m Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2023.04.002_bib41","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2023.04.002_bib42","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","article-title":"Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Drandi","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.hoc.2023.04.002_bib43","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00277-020-04139-7","article-title":"Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in Waldenstr\u00f6m macroglobulinemia","volume":"99","author":"Wu","year":"2020","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.hoc.2023.04.002_bib44","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1002\/ajh.26184","article-title":"Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenstr\u00f6m macroglobulinemia","volume":"96","author":"Demos","year":"2021","journal-title":"Am J Hematol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:20:26Z","timestamp":1760185226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0889858823000369"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Implications of Genomic Profile in Waldenstr\u00f6m Macroglobulinemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}